Primary sclerosing cholangitis differential diagnosis: Difference between revisions
Akshun Kalia (talk | contribs) No edit summary |
Ahmed Younes (talk | contribs) No edit summary |
||
(17 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Primary_sclerosing_cholangitis]] | |||
{{CMG}}; {{AE}}{{DN}} | {{CMG}}; {{AE}}{{DN}}{{Akshun}} | ||
==Overview== | ==Overview== | ||
Line 9: | Line 9: | ||
Primary sclerosing cholangitis must be differentiated from causes of secondary sclerosing cholangitis. These include:<ref name="pmid27653566">{{cite journal |vauthors=Lazaridis KN, LaRusso NF |title=Primary Sclerosing Cholangitis |journal=N. Engl. J. Med. |volume=375 |issue=12 |pages=1161–70 |year=2016 |pmid=27653566 |doi=10.1056/NEJMra1506330 |url=}}</ref><ref name="pmid20101749">{{cite journal |vauthors=Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ |title=Diagnosis and management of primary sclerosing cholangitis |journal=Hepatology |volume=51 |issue=2 |pages=660–78 |year=2010 |pmid=20101749 |doi=10.1002/hep.23294 |url=}}</ref> | Primary sclerosing cholangitis must be differentiated from causes of secondary sclerosing cholangitis. These include:<ref name="pmid27653566">{{cite journal |vauthors=Lazaridis KN, LaRusso NF |title=Primary Sclerosing Cholangitis |journal=N. Engl. J. Med. |volume=375 |issue=12 |pages=1161–70 |year=2016 |pmid=27653566 |doi=10.1056/NEJMra1506330 |url=}}</ref><ref name="pmid20101749">{{cite journal |vauthors=Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ |title=Diagnosis and management of primary sclerosing cholangitis |journal=Hepatology |volume=51 |issue=2 |pages=660–78 |year=2010 |pmid=20101749 |doi=10.1002/hep.23294 |url=}}</ref> | ||
'''Primary sclerosing cholangitis must be differentiated from other causes of jaundice and pruritis:''' | |||
<small> | |||
{| align="center" | {| align="center" | ||
|- | |- | ||
| | | | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | {| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | ||
! | ! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Classification of jaundice based on etiology | ||
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Disease | ! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Disease | ||
! colspan="4" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |History and clinical manifestations | ! colspan="4" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |History and clinical manifestations | ||
Line 56: | Line 36: | ||
! colspan="1" rowspan="1" align="center" style="background:#4479BA; color: #FFFFFF;" |Viral serology | ! colspan="1" rowspan="1" align="center" style="background:#4479BA; color: #FFFFFF;" |Viral serology | ||
|- | |- | ||
| rowspan="6" style="padding: 5px 5px; background: #DCDCDC;" align="center"|Cholestatic Jaundice | |||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Primary sclerosing cholangitis | |||
| | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/↑ | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Beading on MRCP | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Liver biopsy | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Liver biopsy | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" | | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Common bile duct stone | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
Line 211: | Line 105: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |AMA positive | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |AMA positive | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Liver biopsy | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Liver biopsy | ||
|- | |- | ||
Line 240: | Line 120: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Mass on ultrasond | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Mass on ultrasond | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |CT scan for diagnosis | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |CT scan for diagnosis | ||
|- | |- | ||
|} | |} | ||
|} | |} | ||
</small> | |||
<span style="font-size:85%">'''Abbreviations:''' | <span style="font-size:85%">'''Abbreviations:''' | ||
'''[[RUQ]]'''= Right upper quadrant of the abdomen, '''LUQ'''= Left upper quadrant, '''LLQ'''= Left lower quadrant, '''RLQ'''= Right lower quadrant, '''LFT'''= Liver function test, SIRS= [[Systemic inflammatory response syndrome]], '''[[ERCP]]'''= [[Endoscopic retrograde cholangiopancreatography]], '''IV'''= Intravenous, '''N'''= Normal, '''AMA'''= Anti mitochondrial antibodies, '''[[LDH]]'''= [[Lactate dehydrogenase]], '''GI'''= Gastrointestinal, '''CXR'''= Chest X ray, '''IgA'''= [[Immunoglobulin A]], '''IgG'''= [[Immunoglobulin G]], '''IgM'''= [[Immunoglobulin M]], '''CT'''= [[Computed tomography]], '''[[PMN]]'''= Polymorphonuclear cells, '''[[ESR]]'''= [[Erythrocyte sedimentation rate]], '''[[CRP]]'''= [[C-reactive protein]], TS= [[Transferrin saturation]], SF= Serum [[Ferritin]], SMA= [[Superior mesenteric artery]], SMV= [[Superior mesenteric vein]], ECG= [[Electrocardiogram]]</span> | '''[[RUQ]]'''= Right upper quadrant of the abdomen, '''LUQ'''= Left upper quadrant, '''LLQ'''= Left lower quadrant, '''RLQ'''= Right lower quadrant, '''LFT'''= Liver function test, SIRS= [[Systemic inflammatory response syndrome]], '''[[ERCP]]'''= [[Endoscopic retrograde cholangiopancreatography]], '''IV'''= Intravenous, '''N'''= Normal, '''AMA'''= Anti mitochondrial antibodies, '''[[LDH]]'''= [[Lactate dehydrogenase]], '''GI'''= Gastrointestinal, '''CXR'''= Chest X ray, '''IgA'''= [[Immunoglobulin A]], '''IgG'''= [[Immunoglobulin G]], '''IgM'''= [[Immunoglobulin M]], '''CT'''= [[Computed tomography]], '''[[PMN]]'''= Polymorphonuclear cells, '''[[ESR]]'''= [[Erythrocyte sedimentation rate]], '''[[CRP]]'''= [[C-reactive protein]], TS= [[Transferrin saturation]], SF= Serum [[Ferritin]], SMA= [[Superior mesenteric artery]], SMV= [[Superior mesenteric vein]], ECG= [[Electrocardiogram]]</span> | ||
Line 403: | Line 135: | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | {| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Disease | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Disease | ||
| colspan=" | | colspan="10" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Clinical manifestations''' | ||
! colspan="2" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Diagnosis | ! colspan="2" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Diagnosis | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Comments | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Comments | ||
|- | |- | ||
| colspan=" | | colspan="7" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Symptoms''' | ||
! colspan=" | ! colspan="3" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" | Signs | ||
|- | |- | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Abdominal Pain | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Abdominal Pain | ||
Line 415: | Line 147: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Hypo- | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Hypo- | ||
tension | tension | ||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" | Guarding | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" | Guarding | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" | Lab Findings | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" | Lab Findings | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ||
Line 433: | Line 162: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
Line 439: | Line 167: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Increased liver enzymes | * Increased liver enzymes | ||
Line 463: | Line 189: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
Line 470: | Line 194: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Abnormal [[LFT]] | *Abnormal [[LFT]] | ||
Line 485: | Line 208: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
Line 491: | Line 213: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Abnormal [[LFT]] | * Abnormal [[LFT]] | ||
Line 506: | Line 226: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
Line 512: | Line 231: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Hyperbilirubinemia]] | * [[Hyperbilirubinemia]] | ||
Line 529: | Line 246: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Hypo- | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Hypo- | ||
tension | tension | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ||
Line 548: | Line 262: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Increased [[amylase]] / [[lipase]] | * Increased [[amylase]] / [[lipase]] | ||
Line 570: | Line 281: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 576: | Line 286: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Increased [[amylase]] / [[lipase]] | * Increased [[amylase]] / [[lipase]] | ||
Line 595: | Line 303: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 601: | Line 308: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* ↑ [[Alkaline phosphatase]] | * ↑ [[Alkaline phosphatase]] | ||
Line 616: | Line 321: | ||
* [[Mucous membrane pemphigoid|Cicatricial pemphigoid]] | * [[Mucous membrane pemphigoid|Cicatricial pemphigoid]] | ||
* [[Thrombophlebitis|Migratory superficial thrombophlebitis]] (classic [[Trousseau's syndrome]]) | * [[Thrombophlebitis|Migratory superficial thrombophlebitis]] (classic [[Trousseau's syndrome]]) | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Primary biliary cirrhosis]] | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Primary biliary cirrhosis]] | ||
Line 624: | Line 328: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
Line 630: | Line 333: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Increased AMA level, abnormal [[LFTs]] | * Increased AMA level, abnormal [[LFTs]] | ||
Line 650: | Line 351: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Leukocytosis]] | * [[Leukocytosis]] | ||
Line 659: | Line 357: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Fatty food intolerance | * Fatty food intolerance | ||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Biliary colic]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |RUQ | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | |||
* ↑ [[bilirubin]] and [[alkaline phosphatase]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | |||
* Ultrasound | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | |||
|- | |- | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Disease | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Disease | ||
Line 666: | Line 381: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Hypo- | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Hypo- | ||
tension | tension | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Comments | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Comments | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Inflammatory bowel disease]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Inflammatory bowel disease]] | ||
Line 757: | Line 397: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Anti-neutrophil cytoplasmic antibody]] ([[P-ANCA]]) in [[Ulcerative colitis]] | * [[Anti-neutrophil cytoplasmic antibody]] ([[P-ANCA]]) in [[Ulcerative colitis]] | ||
Line 774: | Line 411: | ||
* [[Uveitis]] | * [[Uveitis]] | ||
* [[Arthritis]] | * [[Arthritis]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Whipple's disease]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Whipple's disease]] | ||
Line 822: | Line 418: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Thrombocytopenia]] | * [[Thrombocytopenia]] | ||
Line 848: | Line 441: | ||
* [[Arthritis]] | * [[Arthritis]] | ||
* [[Ascites]] | * [[Ascites]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis|Viral hepatitis]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis|Viral hepatitis]] | ||
Line 881: | Line 448: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in Hep A and E | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in Hep A and E | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in fulminant hepatitis | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in fulminant hepatitis | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in acute | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in acute | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Abnormal LFTs | * Abnormal LFTs | ||
Line 897: | Line 461: | ||
* Hep A and E have fecal-oral route of transmission | * Hep A and E have fecal-oral route of transmission | ||
* Hep B and C transmits via blood transfusion and sexual contact. | * Hep B and C transmits via blood transfusion and sexual contact. | ||
|- | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Disease | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Abdominal Pain | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Fever | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Rigors and chills | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Hypo- | |||
tension | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Comments | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Liver abscess]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Liver abscess]] | ||
Line 904: | Line 484: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* CBC | * CBC | ||
Line 927: | Line 504: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 933: | Line 509: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* High levels of [[Alpha-fetoprotein|AFP]] in serum | * High levels of [[Alpha-fetoprotein|AFP]] in serum | ||
Line 951: | Line 523: | ||
* [[Spider nevi]] | * [[Spider nevi]] | ||
* [[Asterixis]] | * [[Asterixis]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cirrhosis|Cirrhosis]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cirrhosis|Cirrhosis]] | ||
Line 977: | Line 530: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Hypoalbuminemia]] | * [[Hypoalbuminemia]] | ||
Line 1,004: | Line 554: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in cirrhotic patients | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in cirrhotic patients | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Ascitic fluid [[PMN]]>250 cells/mm<small>³</small> | * Ascitic fluid [[PMN]]>250 cells/mm<small>³</small> | ||
Line 1,017: | Line 564: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Ultrasound for evaluation of liver cirrhosis | * Ultrasound for evaluation of liver cirrhosis | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
|- | |- |
Latest revision as of 21:42, 8 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2] Akshun Kalia M.B.B.S.[3]
Overview
Primary sclerosing cholangitis must be differentiated from causes of secondary sclerosing cholangitis.
Differentiating Primary sclerosing cholangitis from other Diseases
Primary sclerosing cholangitis must be differentiated from causes of secondary sclerosing cholangitis. These include:[1][2]
Primary sclerosing cholangitis must be differentiated from other causes of jaundice and pruritis:
|
Abbreviations: RUQ= Right upper quadrant of the abdomen, LUQ= Left upper quadrant, LLQ= Left lower quadrant, RLQ= Right lower quadrant, LFT= Liver function test, SIRS= Systemic inflammatory response syndrome, ERCP= Endoscopic retrograde cholangiopancreatography, IV= Intravenous, N= Normal, AMA= Anti mitochondrial antibodies, LDH= Lactate dehydrogenase, GI= Gastrointestinal, CXR= Chest X ray, IgA= Immunoglobulin A, IgG= Immunoglobulin G, IgM= Immunoglobulin M, CT= Computed tomography, PMN= Polymorphonuclear cells, ESR= Erythrocyte sedimentation rate, CRP= C-reactive protein, TS= Transferrin saturation, SF= Serum Ferritin, SMA= Superior mesenteric artery, SMV= Superior mesenteric vein, ECG= Electrocardiogram
Primary sclerosing cholangitis must be differentiated from other abdominal pain causes:
|
References
- ↑ Lazaridis KN, LaRusso NF (2016). "Primary Sclerosing Cholangitis". N. Engl. J. Med. 375 (12): 1161–70. doi:10.1056/NEJMra1506330. PMID 27653566.
- ↑ Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010). "Diagnosis and management of primary sclerosing cholangitis". Hepatology. 51 (2): 660–78. doi:10.1002/hep.23294. PMID 20101749.